Compare Stocks: PYXS, SANA, ALMS, and KURA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$11.36 +9.8%	$25.63	$3.76 ▼ $31.35	$1.34B	-0.81	2.70 million shs	7.55 million shs
KURA Kura Oncology	$13.15 +0.3%	$11.06	$7.36 ▼ $13.90	$1.17B	0.44	2.32 million shs	1.47 million shs
PYXS Pyxis Oncology	$3.57 -4.8%	$2.94	$1.03 ▼ $5.55	$312.78M	1.34	1.37 million shs	812,150 shs
SANA Sana Biotechnology	$3.92 +0.8%	$3.62	$2.61 ▼ $6.55	$1.16B	2.12	2.46 million shs	2.64 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	+9.76%	-51.06%	-58.11%	-40.40%	+142.74%
KURA Kura Oncology	+0.31%	-0.23%	+38.86%	+50.46%	+55.99%
PYXS Pyxis Oncology	-4.80%	+7.53%	+12.97%	+100.56%	+142.86%
SANA Sana Biotechnology	+0.77%	-4.16%	+15.29%	+46.27%	+31.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$11.36 +9.8%	$25.63	$3.76 ▼ $31.35	$1.34B	-0.81	2.70 million shs	7.55 million shs
KURA Kura Oncology	$13.15 +0.3%	$11.06	$7.36 ▼ $13.90	$1.17B	0.44	2.32 million shs	1.47 million shs
PYXS Pyxis Oncology	$3.57 -4.8%	$2.94	$1.03 ▼ $5.55	$312.78M	1.34	1.37 million shs	812,150 shs
SANA Sana Biotechnology	$3.92 +0.8%	$3.62	$2.61 ▼ $6.55	$1.16B	2.12	2.46 million shs	2.64 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	+9.76%	-51.06%	-58.11%	-40.40%	+142.74%
KURA Kura Oncology	+0.31%	-0.23%	+38.86%	+50.46%	+55.99%
PYXS Pyxis Oncology	-4.80%	+7.53%	+12.97%	+100.56%	+142.86%
SANA Sana Biotechnology	+0.77%	-4.16%	+15.29%	+46.27%	+31.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMS Alumis	2.83	Moderate Buy	$33.27	192.89% Upside
KURA Kura Oncology	2.75	Moderate Buy	$25.40	93.16% Upside
PYXS Pyxis Oncology	2.70	Moderate Buy	$7.50	110.08% Upside
SANA Sana Biotechnology	2.80	Moderate Buy	$9.33	138.10% Upside

Current Analyst Ratings Breakdown

Latest PYXS, SANA, ALMS, and KURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	ALMS Alumis	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
9/2/2026	ALMS Alumis	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$55.00 ➝ $37.00
9/2/2026	ALMS Alumis	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$39.00 ➝ $29.00
9/2/2026	ALMS Alumis	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $25.00
9/2/2026	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$25.00 ➝ $15.00
9/1/2026	ALMS Alumis	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$27.00
9/1/2026	ALMS Alumis	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $25.00
9/1/2026	ALMS Alumis	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/24/2026	KURA Kura Oncology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMS Alumis	$24.05M	61.14	N/A	N/A	$3.49 per share	3.26
KURA Kura Oncology	$67.48M	17.34	N/A	N/A	$0.54 per share	24.35
PYXS Pyxis Oncology	$13.86M	21.48	N/A	N/A	$0.14 per share	25.50
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.52 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMS Alumis	-$243.32M	-$3.86	N/A	N/A	N/A	-5,933.46%	-93.15%	-74.50%	11/12/2026 (Estimated)
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)
PYXS Pyxis Oncology	-$79.62M	-$1.41	N/A	N/A	N/A	N/A	-215.23%	-112.19%	11/2/2026 (Estimated)
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-103.02%	-39.16%	11/5/2026 (Estimated)

Latest PYXS, SANA, ALMS, and KURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ALMS Alumis	-$0.7670	-$1.11	-$0.3430	-$1.11	$3.65 million	$1.66 million
8/13/2026	Q2 2026	PYXS Pyxis Oncology	-$0.35	-$0.40	-$0.05	-$0.40	$0.03 million	N/A
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/11/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMS Alumis	N/A	6.74	6.74
KURA Kura Oncology	0.12	4.73	4.71
PYXS Pyxis Oncology	N/A	1.34	1.34
SANA Sana Biotechnology	N/A	1.38	1.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMS Alumis	N/A
KURA Kura Oncology	N/A
PYXS Pyxis Oncology	39.07%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
ALMS Alumis	33.70%
KURA Kura Oncology	7.60%
PYXS Pyxis Oncology	5.70%
SANA Sana Biotechnology	25.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMS Alumis	N/A	129.43 million	85.82 million	N/A
KURA Kura Oncology	130	88.96 million	82.20 million	Optionable
PYXS Pyxis Oncology	60	83.41 million	78.65 million	Optionable
SANA Sana Biotechnology	380	299.36 million	223.32 million	Optionable

PYXS, SANA, ALMS, and KURA Headlines

Recent News About These Companies

Corient Private Wealth LP Invests $2.19 Million in Sana Biotechnology, Inc. $SANA

September 3 at 3:44 AM | marketbeat.com

Sana Biotechnology to Present at September 2026 Investor Conferences

September 1 at 4:05 PM | globenewswire.com

16,675,173 Shares in Sana Biotechnology, Inc. $SANA Acquired by BlackRock Inc.

September 1 at 3:20 AM | marketbeat.com

Canada Pension Plan Investment Board Purchases Shares of 10,218,400 Sana Biotechnology, Inc. $SANA

August 28, 2026 | marketbeat.com

Deutsche Bank AG Buys New Stake in Sana Biotechnology, Inc. $SANA

August 28, 2026 | marketbeat.com

As U.S.-China biotech race heats up, Seattle makes its case to D.C.

August 27, 2026 | msn.com

As US.-China biotech race heats up, Seattle makes its case to DC

August 27, 2026 | msn.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 5.7% Following Analyst Upgrade

August 27, 2026 | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Upgraded at TD Cowen

August 27, 2026 | americanbankingnews.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Rating of "Moderate Buy" by Analysts

August 26, 2026 | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 5.7% After Analyst Upgrade

August 25, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Rating Upgraded by TD Cowen

August 25, 2026 | marketbeat.com

Bank of America Corp DE Has $8.49 Million Stock Position in Sana Biotechnology, Inc. $SANA

August 25, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Cell Therapy Vision Gains Attention

August 21, 2026 | kalkinemedia.comK

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Analysts

August 21, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.2% - Time to Sell?

August 20, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 8.9% - Still a Buy?

August 19, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA)

August 19, 2026 | theglobeandmail.com

Alphabet Inc. Makes New $9.82 Million Investment in Sana Biotechnology, Inc. $SANA

August 18, 2026 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA): Can Cell Therapy Drive the Next Chapter?

August 15, 2026 | kalkinemedia.comK

Bank of America Issues Pessimistic Forecast for Sana Biotechnology (NASDAQ:SANA) Stock Price

August 14, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS, SANA, ALMS, and KURA Company Descriptions

Alumis NASDAQ:ALMS

$11.36 +1.01 (+9.76%)

As of 09/3/2026 04:00 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Kura Oncology NASDAQ:KURA

$13.15 +0.04 (+0.31%)

As of 09/3/2026 04:00 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Pyxis Oncology NASDAQ:PYXS

$3.57 -0.18 (-4.80%)

As of 09/3/2026 04:00 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Sana Biotechnology NASDAQ:SANA

$3.92 +0.03 (+0.77%)

As of 09/3/2026 04:00 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PYXS, SANA, ALMS, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PYXS, SANA, ALMS, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PYXS, SANA, ALMS, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS, SANA, ALMS, and KURA Company Descriptions

Alumis NASDAQ:ALMS

Kura Oncology NASDAQ:KURA

Pyxis Oncology NASDAQ:PYXS

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PYXS, SANA, ALMS, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PYXS, SANA, ALMS, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PYXS, SANA, ALMS, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS, SANA, ALMS, and KURA Company Descriptions

Alumis NASDAQ:ALMS

Kura Oncology NASDAQ:KURA

Pyxis Oncology NASDAQ:PYXS

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools